Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pcv2 immunogenic compositions and methods of producing such compositions

a technology of immunogenic compositions and compositions, applied in the direction of immunological disorders, antibody medical ingredients, peptide sources, etc., can solve the problems of ineffective vaccines, high extraction procedures, and low amount of orf2 recovered from cells, and achieve the effect of lessening this

Inactive Publication Date: 2009-01-22
BOEHRINGER LNGELHEIM VETMEDICA GMBH
View PDF3 Cites 35 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention provides an improved method for producing and recovering recombinant PCV2 ORF2 protein. This is achieved by infecting susceptible cells with a recombinant viral vector containing PCV2 ORF2 DNA and expressing the protein. The method involves allowing the infection to progress past the typical prior methods of extracting the protein from the cells. The recovered protein is present in high amounts in the supernate of cell cultures, meaning more than about 20 μg / mL supernate. The method also involves using a serum-free insect cell media and a recombinant viral vector containing a PCV2 ORF2 DNA sequence with a multiplicity of infection of 0.3-1.5. The infected cells are then incubated for a period of up to ten days. Overall, this method allows for the efficient production and recovery of recombinant PCV2 ORF2 protein.

Problems solved by technology

However, these procedures have a disadvantage in that the extraction procedures are both costly and time-consuming.
Additionally, the amount of ORF2 recovered from the cells is not very high; consequently, a large number of cells need to be infected by a large number of viral vectors in order to obtain sufficient quantities of the recombinant expressed protein for use in vaccines and the like.
However, such vaccines have been ineffective at conferring protective immunity against PCV2 infection and the clinical signs associated therewith.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pcv2 immunogenic compositions and methods of producing such compositions
  • Pcv2 immunogenic compositions and methods of producing such compositions
  • Pcv2 immunogenic compositions and methods of producing such compositions

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0093]This example compares the relative yields of ORF2 using methods of the present invention with methods that are known in the prior art. Four 1000 mL spinner flasks were each seeded with approximately 1.0×106 Sf+ cells / ml in 300 mL of insect serum free media, Excell 420 (JRH Biosciences, Inc., Lenexa, Kans.). The master cell culture is identified as SF+(Spodoptera frugiperda) Master Cell Stock, passage 19, Lot#N112-095W. The cells used to generate the SF+ Master Cell Stock were obtained from Protein Sciences Corporation, Inc., Meriden, Conn. The SF+ cell line for this example was confined between passages 19 and 59. Other passages will work for purposes of the present invention, but in order to scale the process up for large scale production, at least 19 passages will probably be necessary and passages beyond 59 may have an effect on expression, although this was not investigated. In more detail, the initial SF+ cell cultures from liquid nitrogen storage were grown in Excell 420...

example 2

[0098]This example provides data as to the efficacy of the invention claimed herein. A 1000 mL spinner flask was seeded with approximately 1.0×106 Sf+ cells / ml in 300 mL of Excell 420 media. The flask was then incubated at 27° C. and agitated at 100 rpm. Subsequently, the flask was seeded with 10 mL of PCV2 ORF2 / Bac p+6 (the recombinant baculovirus containing the PCV2 ORF2 gene passaged 6 additional times in the Sf9 insect cells) virus seed with a 0.1 MOI after 24 hours of incubation.

[0099]The flask was then incubated at 27° C. for a total of 6 days. After incubation, the flask was then centrifuged and three samples of the resulting supernatant were harvested and inactivated. The supernatant was inactivated by bringing its temperature to 37±2° C. To the first sample, a 0.4M solution of 2-bromoethyleneamine hydrobromide which had been cyclized to 0.2M binary ethlylenimine (BEI) in 0.3N NaOH is added to the supernatant to give a final concentration of BEI of 5 mM. To the second sample...

example 3

[0101]This example demonstrates that the present invention is scalable from small scale production of recombinant PCV2 ORF2 to large scale production of recombinant PCV2 ORF2. 5.0×105 cells / ml of SF+ cells / ml in 7000 mL of ExCell 420 media was planted in a 20000 mL Applikon Bioreactor. The media and cells were then incubated at 27° C. and agitated at 100 RPM for the next 68 hours. At the 68th hour, 41.3 mL of PCV2 ORF2 Baculovirus MSV+3 was added to 700 mL of ExCell 420 medium. The resultant mixture was then added to the bioreactor. For the next seven days, the mixture was incubated at 27° C. and agitated at 100 RPM. Samples from the bioreactor were extracted every 24 hours beginning at day 4, post-infection, and each sample was centrifuged. The supernatant of the samples were preserved and the amount of ORF2 was then quantified using SDS-PAGE densitometry. The results of this can be seen in Table 3 below:

TABLE 3Day after infection:ORF2 in supernatant (μg / mL)429.33541.33631.33760.67...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
volumeaaaaaaaaaa
volumeaaaaaaaaaa
diameteraaaaaaaaaa
Login to View More

Abstract

An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time-consuming extraction procedures required to separate and recover the recombinant protein from within the cells.

Description

RELATED APPLICATIONS[0001]This application is a divisional of application Ser. No. 11 / 319,975, filed Dec. 29, 2005, which claims the benefit of provisional application Ser. No. 60 / 640,510, filed on Dec. 30, 2004, and application Ser. No. 11 / 034,737, filed on Jan. 13, 2005, the teachings and contents all of which are hereby incorporated by reference.SEQUENCE LISTING[0002]This application contains a sequence listing in paper format and in computer readable format, the teachings and content of which are hereby incorporated by reference.BACKGROUND OF THE INVENTION[0003]1. Field of the Invention[0004]One aspect of the present invention is concerned with the recovery of a protein expressed by open reading frame 2 (ORF2) of porcine circovirus type 2 (PCV2). More particularly, the protein is a recombinant protein expressed by a transfected virus containing recombinant coding sequences for porcine circovirus type 2, open reading frame 2. Still more particularly, the transfected virus is perm...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/12A61P37/04
CPCA61K33/00A61K2039/55555A61K45/06A61K2039/5258A61K2039/55505C07K14/005C12N2710/14143C12N2710/14163C12N2750/10022C12N2750/10034C12N2750/10051C12N2770/10034A61K2039/545A61K2039/552A61K39/12A61P31/00A61P31/12A61P31/20A61P37/00A61P37/04C12N15/10C12N15/09C12N15/11C07K16/00
Inventor EICHMEYER, MARCNITZEL, GREGSCHAEFFER, MERRILL
Owner BOEHRINGER LNGELHEIM VETMEDICA GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com